Systemic lupus erythematosus: A genetic review for advanced practice nurses

Journal of the American Academy of Nurse Practitioners

Volumn 23, Issue 12, 2011, Pages 629-637

  Robinson, Marcia ^a   Sheets Cook, Sarah ^b   Currie, Leanne M ^c  

^a Neighborhood and Family Health Center   (United States)

^b Columbia University School of Nursing ^*  (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Genetics; Lupus; SLE; SLE management; SLE treatment

Indexed keywords

CORTICOSTEROID;

ADULT; ADVANCED PRACTICE NURSING; ANAMNESIS; ARTICLE; CASE REPORT; DISEASE COURSE; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; METHODOLOGY; NURSING; NURSING DIAGNOSIS; PATHOLOGY; PROGNOSIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET RADIATION;

ADRENAL CORTEX HORMONES; ADULT; ADVANCED PRACTICE NURSING; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICAL HISTORY TAKING; NURSING DIAGNOSIS; PROGNOSIS; RISK FACTORS; ULTRAVIOLET RAYS;

EID: 83255186833     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2011.00675.x     Document Type: Article

References (69)

1. Adelowo, O. O., & Oguntona, S. A. (2009). Pattern of systemic lupus erythematosus among Nigerians. Clinical Rheumatology, 28(6), 699-703.
2. Alarcon, G. S., McGwin, G., Jr., Bastian, H. M., Fessler, B. J., Baethge, B. A., Friedman, A. W., & Reveille, J. D. (2002). SLE in three ethnic groups XIII. The 'weighted' criteria as predictors of damage. Lupus, 11(5), 329-331.
3. Allison, A. C., & Eugui, E. M. (2000). Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47(2-3), 85-118.
4. Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., et al. (2003). Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New England Journal of Medicine, 349(16), 1526-1533.
5. Aringer, M., Smolen, J. S., & Graninger, W. B. (1998). Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis and Rheumatism, 41(3), 414-420.
6. Ayan, C., & Martin, V. (2007). Systemic lupus erythematosus and exercise. Lupus, 16(1), 5-9.
7. Baecklund, E., Sundstrom, C., Ekbom, A., Catrina, A. I., Biberfeld, P., Feltelius, N., et al. (2003). Lymphoma subtypes in patients with rheumatoid arthritis: Increased proportion of diffuse large B cell lymphoma. Arthritis and Rheumatism, 48(6), 1543-1550.
8. Barnes, T. C., & Bucknall, R. C. (2004). Vitamin D deficiency in a patient with systemic lupus erythematosus. Rheumatology (Oxford), 43(3), 393-394.
9. Bautista, J. F., Kelly, J. A., Harley, J. B., & Gray-McGuire, C. (2008). Addressing genetic heterogeneity in complex disease: Finding seizure genes in systemic lupus erythematosus. Epilepsia, 49(3), 527-530.
10. Bernatsky, S., Boivin, J. F., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., et al. (2006). Mortality in systemic lupus erythematosus. Arthritis and Rheumatism, 54(8), 2550-2557.
11. Bernatsky, S., Clarke, A., & Ramsey-Goldman, R. (2002). Malignancy and systemic lupus erythematosus. Current Rheumatology Reports, 4(4), 351-358.
12. Bernatsky, S., Ramsey-Goldman, R., Rajan, R., Boivin, J. F., Joseph, L., Lachance, S., et al. (2005). Non-Hodgkin's lymphoma in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 64(10), 1507-1509.
13. Carreno, L., Lopez-Longo, F. J., Gonzalez, C. M., & Monteagudo, I. (2002). Treatment options for juvenile-onset systemic lupus erythematosus. Paediatric Drugs, 4(4), 241-256.
14. Chan, T. M., Li, F. K., Wong, R. W., Wong, K. L., Chan, K. W., & Cheng, I. K. (1995). Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron, 71(3), 321-327.
15. Daltroy, L. H., Robb-Nicholson, C., Iversen, M. D., Wright, E. A., & Liang, M. H. (1995). Effectiveness of minimally supervised home aerobic training in patients with systemic rheumatic disease. British Journal of Rheumatology, 34(11), 1064-1069.
16. Duffy, K. N., Duffy, C. M., & Gladman, D. D. (1991). Infection and disease activity in systemic lupus erythematosus: A review of hospitalized patients. Journal of Rheumatology, 18(8), 1180-1184.
17. Felson, D. T., & Anderson, J. (1984). Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. New England Journal of Medicine, 311(24), 1528-1533.
18. Fernando, M. M. A., Stevens, C. R., Sabeti, P. C., Walsh, E. C., McWhinnie, A. J. M., Shah, A., et al. (2007). Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genetics, 3(11), e192, 2109-2121.
19. Frank, M. B., McArthur, R., Harley, J. B., & Fujisaku, A. (1990). Anti-Ro(SSA) autoantibodies are associated with T cell receptor beta genes in systemic lupus erythematosus patients. Journal of Clinical Investigation, 85(1), 33-39.
20. Gescuk, B. D., & Davis, J. C., Jr. (2002). Novel therapeutic agents for systemic lupus erythematosus. Current Opinion in Rheumatology, 14(5), 515-521.
21. Ghaussy, N. O., Sibbitt, W., Jr., Bankhurst, A. D., & Qualls, C. R. (2003). Cigarette smoking and disease activity in systemic lupus erythematosus. Journal of Rheumatology, 30(6), 1215-1221.
22. Gill, J. M., Quisel, A. M., Rocca, P. V., & Walters, D. T. (2003). Diagnosis of systemic lupus erythematosus. American Family Physician, 68(11), 2179-2186.
23. Ginzler, E. M., & Moldovan, I. (2004). Systemic lupus erythematosus trials: Successes and issues. Current Opinion in Rheumatology, 16(5), 499-504.
24. Goldblatt, F., & Isenberg, D. A. (2005). New therapies for systemic lupus erythematosus. Clinical and Experimental Immunology, 140(2), 205-212.
25. Hamilton, R. G., Harley, J. B., Bias, W. B., Roebber, M., Reichlin, M., Hochberg, M. C., et al. (1988). Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis and Rheumatism, 31(4), 496-505.
26. Harley, J. B., Alexander, E. L., Bias, W. B., Fox, O. F., Provost, T. T., Reichlin, M., et al. (1986). Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjogren's syndrome. Arthritis and Rheumatism, 29(2), 196-206.
27. Hess, D. C. (1994). Models for central nervous system complications of antiphospholipid syndrome. Lupus, 3(4), 253-257.
28. Ho, A., Barr, S. G., Magder, L. S., & Petri, M. (2001). A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 44(10), 2350-2357.
29. Hochberg, M. C. (1987). The application of genetic epidemiology to systemic lupus erythematosus. Journal of Rheumatology, 14(5), 867-869.
30. Horton, R., Wilming, L., Rand, V., Lovering, R. C., Bruford, E. A., Khodiyar, V. K., et al. (2004). Gene map of the extended human MHC. Nature Reviews Genetics, 5(12), 889-899.
31. Huether, S. E. a. M., & Kathryn, L. (2000). Understanding pathophysiology (2nd ed.). St Louis, MO: Mosby, Inc.
32. Illei, G. G., Tackey, E., Lapteva, L., & Lipsky, P. E. (2004). Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis and Rheumatism, 50(6), 1709-1720.
33. Jayne, D., & Tyndall, A. (2004). Autologous stem cell transplantation for systemic lupus erythematosus. Lupus, 13(5), 359-365.
34. Kamen, D., & Aranow, C. (2008). Vitamin D in systemic lupus erythematosus. Current Opinion in Rheumatology, 20(5), 532-537.
35. Kang, I., & Park, S. H. (2003). Infectious complications in SLE after immunosuppressive therapies. Current Opinion in Rheumatology, 15(5), 528-534.
36. Kasitanon, N., Magder, L. S., & Petri, M. (2006). Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore), 85(3), 147-156.
37. Lappegard, K. T., Christiansen, D., Pharo, A., Thorgersen, E. B., Hellerud, B. C., Lindstad, J., et al. (2009). Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proceedings of the National Academy of Sciences USA, 106(37), 15861-15866.
38. Lin, J. H., Dutz, J. P., Sontheimer, R. D., & Werth, V. P. (2007). Pathophysiology of cutaneous lupus erythematosus. Clinical Reviews in Allergy and Immunology, 33(1-2), 85-106.
39. Lindelof, B., Sigurgeirsson, B., Gabel, H., & Stern, R. S. (2000). Incidence of skin cancer in 5356 patients following organ transplantation. British Journal of Dermatology, 143(3), 513-519.
40. Manzi, S., Selzer, F., Sutton-Tyrrell, K., Fitzgerald, S. G., Rairie, J. E., Tracy, R. P., et al. (1999). Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis and Rheumatism, 42(1), 51-60.
41. Millet, A., Decaux, O., Perlat, A., Grosbois, B., & Jego, P. (2009). Systemic lupus erythematosus and vaccination. European Journal of Internal Medicine, 20(3), 236-241.
42. Nath, S. K., Kilpatrick, J., & Harley, J. B. (2004) Genetics of human systemic lupus erythematosus: the emerging picture. [Review][65 refs]. Current Opinion in Immunology, 16(6), 794-800.
43. Nived, O., Johansen, P. B., & Sturfelt, G. (1993). Standardized ultraviolet-A exposure provokes skin reaction in systemic lupus erythematosus. Lupus, 2(4), 247-250.
44. Obermoser, G., & Zelger, B. (2008). Triple need for photoprotection in lupus erythematosus. Lupus, 17(6), 525-527.
45. Parker, B. J., & Bruce, I. N. (2007). High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus, 16(6), 387-393.
46. Petri, M. (2004). Cyclophosphamide: New approaches for systemic lupus erythematosus. Lupus, 13(5), 366-371.
47. Pope, J., Jerome, D., Fenlon, D., Krizova, A., & Ouimet, J. (2003). Frequency of adverse drug reactions in patients with systemic lupus erythematosus. Journal of Rheumatology, 30(3), 480-484.
48. Ramos, P. S., Kelly, J. A., Gray-McGuire, C., Bruner, G. R., Leiran, A. N., Meyer, C. M., et al. (2006). Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Genes & Immunity, 7(5), 417-432.
49. Reichlin, M. (1986). Significance of the Ro antigen system. Journal of Clinical Immunology, 6(5), 339-348.
50. Rigby, R. J., & Vinuesa, C. G. (2008). SiLEncing SLE: The power and promise of small noncoding RNAs. Current Opinion in Rheumatology, 20(5), 526-531.
51. Ruiz-Irastorza, G., Egurbide, M. V., Olivares, N., Martinez-Berriotxoa, A., & Aguirre, C. (2008). Vitamin D deficiency in systemic lupus erythematosus: Prevalence, predictors and clinical consequences. Rheumatology (Oxford), 47(6), 920-923.
52. Scofield, R. H., Bruner, G. R., Kelly, J. A., Kilpatrick, J., Bacino, D., Nath, S. K., et al. (2003). Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and 11p13. Blood, 101(3), 992-997.
53. Sestak, A. L., Nath, S. K., Sawalha, A. H., & Harley, J. B. (2007). Current status of lupus genetics. Arthritis Research & Therapy, 9(3), 210.
54. Shai, R., Quismorio, F. P., Jr., Li, L., Kwon, O. J., Morrison, J., Wallace, D. J., et al. (1999). Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Human Molecular Genetics, 8(4), 639-644.
55. Shinjo, S. K. (2009). Systemic lupus erythematosus in the elderly: Antimalarials in disease remission. Rheumatology International, 29(9), 1087-1090.
56. Smith, C. D., & Cyr, M. (1988). The history of lupus erythematosus. From Hippocrates to Osler. Rheumatic Disease Clinics of North America, 14(1), 1-14.
57. Smolen, J. S. (2002). Therapy of systemic lupus erythematosus: A look into the future. Arthritis Research, 4(Suppl. 3), S25-S30.
58. Smolen, J. S., Morimoto, C., Steinberg, A. D., Wolf, A., Schlossman, S. F., Steinberg, R. T., et al. (1985). Systemic lupus erythematosus: Delineation of subpopulations by clinical, serologic, and T cell subset analysis. American Journal of the Medical Sciences, 289(4), 139-147.
59. Stanic, A. K., Stein, C. M., Morgan, A. C., Fazio, S., Linton, M. F., Wakeland, E. K., et al. (2006). Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proceeding of the National Academy of Sciences USA, 103(18), 7018-7023.
60. Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., McShane, D. J., Rothfield, N. F., et al. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism, 25(11), 1271-1277.
61. Tench, C. M., McCarthy, J., McCurdie, I., White, P. D., & D'Cruz, D. P. (2003). Fatigue in systemic lupus erythematosus: A randomized controlled trial of exercise. Rheumatology (Oxford), 42(9), 1050-1054.
62. Thudi, A., Yin, S., Wandstrat, A. E., Li, Q. Z., & Olsen, N. J. (2008). Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. American Journal of the Medical Sciences, 335(2), 99-104.
63. Tierney, L. M., et al. (2005). Current medical diagnosis and treatment (44th ed.). San Francisco, CA: Lange Medical Books/McGraw Hill.
64. Urowitz, M. B., & Gladman, D. D. (2000). How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford), 39(3), 238-244.
65. Urowitz, M. B., Gladman, D. D., Tom, B. D., Ibanez, D., & Farewell, V. T. (2008). Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. Journal of Rheumatology, 35(11), 2152-2158.
66. Vratsanos, G. S., Jung, S., Park, Y. M., & Craft, J. (2001). CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: A model to explain spontaneous T cell activation in lupus. Journal of Experimental Medicine, 193(3), 329-337.
67. Vyse, T. J., & Todd, J. A. (1996). Genetic analysis of autoimmune disease. Cell, 85(3), 311-318.
68. Walport, M. J. (1993). The Roche Rheumatology Prize Lecture. Complement deficiency and disease. British Journal of Rheumatology, 32(4), 269-273.
69. Zonana-Nacach, A., Barr, S. G., Magder, L. S., & Petri, M. (2000). Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis and Rheumatism, 43(8), 1801-1808.